Clinical Trial Update: Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AZD6738 (ceralasertib) in combination with immunotherapy for Non-Small Cell Lung Cancer; the study is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ceralasertib (AZD6738) (ceralasertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING